X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.globenewswire.com/news-release/2024/04/16/2863470/30597/en/Intra-Cellular-Therapies-Announces-Positive-Phase-3-Topline-Results-from-Study-501-Evaluating-Lumateperone-as-Adjunctive-Therapy-in-Patients-with-Major-Depressive-Disorder.html
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-lumateperone-tosylate-capsules-105-mg-and-21-mg-85379.pdf
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-lumateperone-tosylate-capsules-42-mg-27135.pdf
https://www.globenewswire.com/news-release/2022/04/25/2427982/30597/en/Intra-Cellular-Therapies-Announces-FDA-Approval-of-New-Dosage-Strengths-for-CAPLYTA-lumateperone-for-Specific-Patient-Populations.html
https://www.fiercepharma.com/pharma/intra-cellular-scores-another-fda-nod-for-caplyta-one-for-bipolar-disorder
https://www.globenewswire.com/news-release/2021/12/20/2355071/30597/en/Intra-Cellular-Therapies-Announces-U-S-FDA-Approval-of-CAPLYTA-lumateperone-for-the-Treatment-of-Bipolar-Depression-in-Adults.html
https://www.globenewswire.com/news-release/2021/09/27/2303499/30597/en/Intra-Cellular-Therapies-Announces-Publication-of-Lumateperone-Pivotal-Phase-3-Study-in-Bipolar-Depression-in-The-American-Journal-of-Psychiatry.html
https://www.globenewswire.com/news-release/2021/06/07/2242673/30597/en/CAPLYTA-lumateperone-Schizophrenia-Safety-and-Tolerability-Profile-Published-in-the-Journal-International-Clinical-Psychopharmacology.html
https://www.globenewswire.com/fr/news-release/2021/04/22/2214937/30597/en/Intra-Cellular-Therapies-Announces-Investor-Webcast-and-Presentations-on-Lumateperone-Programs-at-the-Upcoming-American-Psychiatric-Association-APA-Annual-Meeting.html
https://www.globenewswire.com/news-release/2021/01/21/2162102/0/en/CAPLYTA-lumateperone-Open-Label-Safety-Switching-Study-in-Patients-with-Schizophrenia-Published-in-the-Journal-Schizophrenia-Research.html
https://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-announces-initiation-clinical-trials
https://seekingalpha.com/news/3612432-intra-cellularsplus-74-on-positive-lumateperone-data-in-bipolar-patients
https://www.biospace.com/article/releases/intra-cellular-therapies-announces-availability-of-caplyta-lumateperone-for-adult-patients-with-schizophrenia/
https://www.globenewswire.com/news-release/2020/02/20/1988312/0/en/Pivotal-Study-of-CAPLYTA-lumateperone-for-the-Treatment-of-Schizophrenia-in-Adults-Published-in-JAMA-Psychiatry.html
https://www.fiercepharma.com/pharma/intra-cellular-after-fda-review-twists-and-turns-nabs-nod-for-schizophrenia-drug-caplyta
https://xconomy.com/new-york/2019/08/05/dog-toxicity-concerns-extend-fdas-review-of-intra-cellular-neuro-drug/
Market Place
Share 
